Changes Ahead for Squamous NSCLC Care

Immunotherapy’s impact is increasing

As soon as a year from now, look for a “completely different paradigm” in the care of squamous non-small cell lung cancer, says Cleveland Clinic medical oncologist James Stevenson, MD.  Dr. Stevenson discussed his outlook in detail at the recent 2016 OncLive State of the Science Summit on Metastatic Non–Small Cell Lung Cancer.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

What changes to expect? Immunotherapy moves to the frontline while chemotherapy shifts to a second-line treatment. Read the entire Q&A with Dr. Stevenson.